Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 57.85M P/E - EPS this Y -11.20% Ern Qtrly Grth -
Income -61.23M Forward P/E -1.39 EPS next Y -5.90% 50D Avg Chg 3.00%
Sales 7.16M PEG -0.06 EPS past 5Y - 200D Avg Chg -11.00%
Dividend N/A Price/Book 0.82 EPS next 5Y 17.00% 52W High Chg -50.00%
Recommedations 2.50 Quick Ratio 3.33 Shares Outstanding 5.48M 52W Low Chg 44.00%
Insider Own 32.97% ROA -33.87% Shares Float 3.63M Beta 0.61
Inst Own 13.15% ROE -98.95% Shares Shorted/Prior 42.60K/19.61K Price 1.11
Gross Margin 70.46% Profit Margin - Avg. Volume 104,867 Target Price 36.00
Oper. Margin -175.22% Earnings Date May 2 Volume 75,741 Change 1.83%
About Assembly Biosciences, Inc.

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research, as well as a partnership with Gilead Sciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Assembly Biosciences, Inc. News
04/09/24 Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
03/28/24 Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
02/08/24 Assembly Biosciences Announces Effective Date of Reverse Stock Split
01/15/24 This Assembly Biosciences Insider Increased Their Holding In The Last Year
01/04/24 Assembly Biosciences Provides Anticipated Development Milestones for 2024
11/10/23 Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/10/23 Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
11/08/23 Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
11/08/23 Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
06:00 AM Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
10/11/23 Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
10/02/23 Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
09/19/23 Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
09/06/23 We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
08/09/23 Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
07:00 AM Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
06/21/23 Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
06/07/23 Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
05/23/23 Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
05/04/23 Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
ASMB Chatroom

User Image Hanswursti Posted - 5 hours ago

$ASMB lol 😅 Bad News ahead. Better Sell before It’s too Late.

User Image BioMan122 Posted - 6 hours ago

$ASMB bad news ante portas? i really hope not!

User Image BioMan122 Posted - 6 hours ago

$ASMB i knew it 😪

User Image Logout Posted - 7 hours ago

$ASMB do you know it? bought today. i buy on bad day and hold. https://www.sharedeals.de/assembly-biosciences-beschleunigt-entwicklung-jetzt-wird-es-ernst/

User Image onemillion2012 Posted - 9 hours ago

$VNDA stay strong. A cheap offer. The need to double the amount. So no dealer there. We are better of alone. Buylist $nktr $asmb $bolt All on speciel sale today.

User Image HansDampfMaschine Posted - 10 hours ago

@BioMan122 @onemillion2012 @Anshoo technically there should be a lot of german shareholders. Alexander Schornstein has more then 10% and he is the head of the german community sharedeals.de they are promoting this stock for some time. Alot of their uses claim to own $ASMB so there should be a lot of german shareholders.

User Image BioMan122 Posted - 10 hours ago

$ASMB it seems $ASMB is disappointing us one more time

User Image Logout Posted - 12 hours ago

$ASMB Still strong. German buyers. And further.

User Image onemillion2012 Posted - 13 hours ago

@johnkimble true.. this have the potentiale to be one off the Best stocks in 2024. A better call would be $asmb

User Image onemillion2012 Posted - 16 hours ago

$ASMB Alex we need you. Keep buying with the Germen friends. We need to see $1 by tommorrow.

User Image wonapenny Posted - 23 hours ago

$ASMB I’m thinking the next batch of 13F forms releasing 5/15 will show a nice increase in institutional investment given the steady uptrend on no news🤞🤞🤞

User Image SearchFor911 Posted - 1 day ago

$ASMB max 4 weeks until next news 🚀

User Image Logout Posted - 1 day ago

$ASMB $ALGS

User Image Gerard0904 Posted - 1 day ago

$ASMB : nice bullish pattern just enjoy the ride

User Image Logout Posted - 1 day ago

$ASMB Could continue to remain stable. It's a steady increase. Slowly more and more long-term investors and those who are waiting for news are coming. If I sell now, I'll run after it again and only have losses. I stay relaxed. This stock is incredible.

User Image BioMan122 Posted - 2 days ago

$ASMB unbelievable on such a day

User Image SearchFor911 Posted - 2 days ago

$ASMB rock solid in this market.

User Image Logout Posted - 2 days ago

$ASMB its time to wonder. yes, beautiful trend and positiv news expected in near future 🚀🚀🚀🚀🚀🚀

User Image BioMan122 Posted - 2 days ago

$ASMB wow, strong! 🤩

User Image Logout Posted - 2 days ago

$ASMB

User Image warpdrive1 Posted - 5 days ago

$ASMB volume decreasing....

User Image warpdrive1 Posted - 5 days ago

$ASMB hanging man candlestick today

User Image BioMan122 Posted - 5 days ago

$ASMB

User Image Logout Posted - 5 days ago

$ASMB

User Image Stronx Posted - 5 days ago

$ASMB Beautiful trend 📈 just a good pr and we fly 💥

User Image SearchFor911 Posted - 5 days ago

$ASMB @Gel021 you still around man? Hope you switched your side for things to come.

User Image onemillion2012 Posted - 5 days ago

That was a beutifull call yesterday from my side. Congratulation to those of you buying $nktr. $asmb if it go to $16 then it will move fast to $19. Good Luck..

User Image Hevchen Posted - 6 days ago

$ASMB

User Image Marc_bullish Posted - 6 days ago

$ASMB 15,24$. 🙌🏻

User Image Stronx Posted - 6 days ago

$ASMB smack that 15$

Analyst Ratings
HC Wainwright & Co. Neutral Apr 1, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Schornstein Alexander 10% Owner 10% Owner Jan 17 Buy 0.79 645,080 509,613 8,209,372 01/19/24
Okazaki Jason A CEO and President CEO and President Aug 02 Sell 1.0879 11,827 12,867 164,786 08/03/23
McHutchison John G Director Director May 22 Sell 1.04 25,972 27,011 169,160 05/24/23
Bjorkquist Jeanette M Principal Accounting.. Principal Accounting Officer May 22 Sell 1.04 274 285 27,532 05/24/23
Delaney William E IV Chief Scientific Off.. Chief Scientific Officer May 22 Sell 1.04 6,561 6,823 116,437 05/24/23
Okazaki Jason A CEO and President CEO and President May 22 Sell 1.04 6,561 6,823 126,613 05/24/23
McHutchison John G Director Director Mar 30 Sell 0.8232 14,883 12,252 177,632 03/31/23
Bjorkquist Jeanette M Principal Accounting.. Principal Accounting Officer Feb 16 Sell 0.82 774 635 23,806 03/31/23
Delaney William E IV Chief Scientific Off.. Chief Scientific Officer Mar 29 Sell 0.8232 3,421 2,816 85,498 03/31/23
McHutchison John G Chief Executive Offi.. Chief Executive Officer Aug 08 Sell 2.1277 12,314 26,200 192,515 08/10/22
Samar Michael P. Chief Financial Offi.. Chief Financial Officer Jul 25 Sell 2.2174 2,020 4,479 77,228 07/26/22
Delaney William E IV Chief Scientific Off.. Chief Scientific Officer May 31 Sell 1.9224 4,164 8,005 76,419 06/02/22
Samar Michael P. Chief Financial Offi.. Chief Financial Officer Mar 29 Sell 2.17 2,285 4,958 76,748 03/31/22
Stamm Luisa M Chief Medical Office.. Chief Medical Officer Mar 29 Sell 2.17 1,038 2,252 40,315 03/31/22
Delaney William E IV Chief Scientific Off.. Chief Scientific Officer Mar 29 Sell 2.17 1,038 2,252 78,083 03/31/22
Okazaki Jason A Chief Operating Offi.. Chief Operating Officer Mar 29 Sell 2.17 1,269 2,754 94,614 03/31/22
McHutchison John G CEO and President CEO and President Mar 29 Sell 2.17 4,614 10,012 204,829 03/31/22
Okazaki Jason A Chief Operating Offi.. Chief Operating Officer Mar 28 Sell 2.2445 4,617 10,363 64,633 03/29/22